250 related articles for article (PubMed ID: 28837524)
21. Endoscopic Prediction of Crohn's Disease Postoperative Recurrence.
De Cruz P; Hamilton AL; Burrell KJ; Gorelik A; Liew D; Kamm MA
Inflamm Bowel Dis; 2022 May; 28(5):680-688. PubMed ID: 34231852
[TBL] [Abstract][Full Text] [Related]
22. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.
Brooks AJ; Sebastian S; Cross SS; Robinson K; Warren L; Wright A; Marsh AM; Tsai H; Majeed F; McAlindon ME; Preston C; Hamlin PJ; Lobo AJ
J Crohns Colitis; 2017 Dec; 11(12):1456-1462. PubMed ID: 25311864
[TBL] [Abstract][Full Text] [Related]
23. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study.
Sorrentino D; Terrosu G; Paviotti A; Geraci M; Avellini C; Zoli G; Fries W; Danese S; Occhipinti P; Croatto T; Zarifi D
Dig Dis Sci; 2012 May; 57(5):1341-8. PubMed ID: 22252267
[TBL] [Abstract][Full Text] [Related]
24. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
[TBL] [Abstract][Full Text] [Related]
25. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
[TBL] [Abstract][Full Text] [Related]
26. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease.
Vasudevan A; Raghunath A; Anthony S; Scanlon C; Sparrow MP; Gibson PR; van Langenberg DR
Dig Dis Sci; 2019 Jun; 64(6):1622-1631. PubMed ID: 30560332
[TBL] [Abstract][Full Text] [Related]
27. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Roblin X; Williet N; Boschetti G; Phelip JM; Del Tedesco E; Berger AE; Vedrines P; Duru G; Peyrin-Biroulet L; Nancey S; Flourie B; Paul S
Gut; 2020 Jul; 69(7):1206-1212. PubMed ID: 31980448
[TBL] [Abstract][Full Text] [Related]
28. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.
Yoshihara T; Shinzaki S; Kawai S; Fujii H; Iwatani S; Yamaguchi T; Araki M; Hiyama S; Inoue T; Hayashi Y; Watabe K; Iijima H; Takehara T
Inflamm Bowel Dis; 2017 Dec; 23(12):2172-2179. PubMed ID: 28945638
[TBL] [Abstract][Full Text] [Related]
29. Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study.
Eberhardson M; Söderling JK; Neovius M; Cars T; Myrelid P; Ludvigsson JF; Askling J; Ekbom A; Olén O
Aliment Pharmacol Ther; 2017 Sep; 46(6):589-598. PubMed ID: 28752637
[TBL] [Abstract][Full Text] [Related]
30. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
31. The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease.
Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
Inflamm Bowel Dis; 2023 May; 29(5):716-725. PubMed ID: 35762666
[TBL] [Abstract][Full Text] [Related]
32. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease.
Gu B; Venkatesh K; Williams AJ; Ng W; Corte C; Gholamrezaei A; Ghaly S; Xuan W; Paramsothy S; Connor S
World J Gastroenterol; 2022 Jun; 28(23):2597-2608. PubMed ID: 35949350
[TBL] [Abstract][Full Text] [Related]
33. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Tursi A; Mocci G; Lorenzetti R; Allegretta L; Brandimarte G; Cassieri C; Colucci R; De Medici A; Faggiani R; Ferronato A; Fiorella S; Forti G; Franceschi M; Gallina S; Giorgetti G; Grasso G; Larussa T; Luzza F; Penna A; Pica R; Piergallini S; Porciello S; Pranzo G; Rodino' S; Scorza S; Sebkova L; Zampaletta C; Elisei W; Picchio M
Eur J Gastroenterol Hepatol; 2021 May; 33(5):670-679. PubMed ID: 33741797
[TBL] [Abstract][Full Text] [Related]
34. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
[TBL] [Abstract][Full Text] [Related]
35. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Regueiro M; Feagan BG; Zou B; Johanns J; Blank MA; Chevrier M; Plevy S; Popp J; Cornillie FJ; Lukas M; Danese S; Gionchetti P; Hanauer SB; Reinisch W; Sandborn WJ; Sorrentino D; Rutgeerts P;
Gastroenterology; 2016 Jun; 150(7):1568-1578. PubMed ID: 26946343
[TBL] [Abstract][Full Text] [Related]
36. Effect of a concomitant elemental diet with maintenance anti-tumor necrosis factor-α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study.
Hirai F; Ishida T; Takeshima F; Yamamoto S; Yoshikawa I; Ashizuka S; Inatsu H; Mitsuyama K; Sou S; Iwakiri R; Nozaki R; Ohi H; Esaki M; Iida M; Matsui T;
J Gastroenterol Hepatol; 2019 Jan; 34(1):132-139. PubMed ID: 29935082
[TBL] [Abstract][Full Text] [Related]
37. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
Candia R; Bravo-Soto GA; Monrroy H; Hernandez C; Nguyen GC
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012328. PubMed ID: 32746500
[TBL] [Abstract][Full Text] [Related]
38. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.
Plevris N; Jenkinson PW; Arnott ID; Jones GR; Lees CW
Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):32-37. PubMed ID: 31567638
[TBL] [Abstract][Full Text] [Related]
39. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
[TBL] [Abstract][Full Text] [Related]
40. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
